Lantern Pharma Closes $4.4M Offering, Plans AI Platform Spin-Off

summarizeSummary

Lantern Pharma Inc. closed a registered direct offering raising $4.4 million upfront, with potential for an additional $4.85 million from warrants, and announced plans to spin off its AI platform, withZeta.ai, into an independent entity.

check_boxKey Events

• Registered Direct Offering Closed

  The company closed a registered direct offering, raising approximately $4.4 million in gross proceeds from the sale of 2,135,923 shares of common stock (or pre-funded warrants in lieu thereof) at $2.06 per share/pre-funded warrant.

• Concurrent Private Placement of Warrants

  In a concurrent private placement, the company issued unregistered warrants to purchase up to 2,135,923 shares of common stock. These warrants have an exercise price of $2.27 per share, are exercisable six months after issuance, and expire in five years, potentially raising an additional $4.85 million.

• Strategic AI Platform Spin-off Planned

  Lantern Pharma announced plans to create an independent business entity for its AI platform, withZeta.ai, under the leadership of CEO Mr. Panna Sharma. The goal is to access dedicated funding and potentially achieve separate valuation multiples, with the entity possibly becoming a newly listed company.

• ATM Program Suspended

  The company suspended offers and sales under its existing At-The-Market (ATM) Sales Agreement, although the agreement remains in full force and effect.

auto_awesomeAnalysis

This filing confirms the closing of a registered direct offering and concurrent private placement, providing Lantern Pharma with $4.4 million in gross proceeds upfront and potential for an additional $4.85 million from warrant exercises. This capital infusion is critical for a company that previously indicated a 'going concern' warning, extending its operational runway. However, the offering is highly dilutive, representing up to 26% of the company's market capitalization if all warrants are exercised, and was priced at a significant discount ($2.06 per share/pre-funded warrant, with warrants at a $2.27 exercise price) compared to the current stock price of $3.19. The strategic plan to spin off the AI platform, withZeta.ai, into an independent, potentially publicly listed entity is a significant long-term move aimed at unlocking value and securing dedicated funding for this asset. The suspension of the existing ATM program indicates a shift in the company's financing strategy.